BioView Ltd. (TASE:BIOV) has received an order for three of its cancer screening systems from the Massachusetts General Hospital Cancer Research Institute. The order is worth NIS 1.7 million. The systems will be installed at three leading cancer institutes - MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, and Dana Farber Cancer Institute - as part of the next stage in the development of the Circulating Tumor Cells (CTC) application at Massachusetts General Hospital cancer trial.
New studies by top US doctors resulted in a breakthrough in cancer research, by finding that a test, similar to a blood test, can discover single tumor cells in the bloodstream. This opens the possibility of personalized cancer treatments and the development of new cancer drugs.
BioView's cancer screening systems are a key tool in these studies. The company believes that further progress in the studies could boost sales of its systems. The BioView cancer screening systems can automatically identify tumor cells and differentiate between them and other cells, a critical factor considering that billions of blood cells are taken in every blood sample.
The system uses algorithms to separate and identify cell forms and color. BioView and Massachusetts General Hospital engineers jointly developed the system. Following the automatic screening, a researcher needs only a few minutes at a computer screen to confirm the results.
BioView's share price rose 9.8% in early trading to NIS 2.59, giving a market cap of NIS 34 million.
Published by Globes [online], Israel business news - www.globes-online.com - on February 20, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011